ENTITY

argenx (ARGX BB)

1
Analysis
Health Care • Netherlands
argenx is a global immunology company focused on developing and commercializing antibody-based medicines for severe autoimmune diseases. Its flagship product, VYVGART (efgartigimod), is approved for generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is headquartered in Amsterdam, the Netherlands, and was founded in 2008.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x